JP2016501828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501828A5 JP2016501828A5 JP2015528691A JP2015528691A JP2016501828A5 JP 2016501828 A5 JP2016501828 A5 JP 2016501828A5 JP 2015528691 A JP2015528691 A JP 2015528691A JP 2015528691 A JP2015528691 A JP 2015528691A JP 2016501828 A5 JP2016501828 A5 JP 2016501828A5
- Authority
- JP
- Japan
- Prior art keywords
- nmda receptor
- pharmaceutical composition
- receptor antagonist
- prepared
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 8
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 claims 2
- 229960004184 ketamine hydrochloride Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692380P | 2012-08-23 | 2012-08-23 | |
| US61/692,380 | 2012-08-23 | ||
| PCT/US2013/056424 WO2014031975A1 (en) | 2012-08-23 | 2013-08-23 | Anxiolytic composition, formulation and method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018124196A Division JP6771512B2 (ja) | 2012-08-23 | 2018-06-29 | 抗不安薬組成物、製剤および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501828A JP2016501828A (ja) | 2016-01-21 |
| JP2016501828A5 true JP2016501828A5 (enExample) | 2016-10-13 |
| JP6722453B2 JP6722453B2 (ja) | 2020-07-15 |
Family
ID=50148531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015528691A Active JP6722453B2 (ja) | 2012-08-23 | 2013-08-23 | 抗不安薬組成物、製剤および使用方法 |
| JP2018124196A Active JP6771512B2 (ja) | 2012-08-23 | 2018-06-29 | 抗不安薬組成物、製剤および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018124196A Active JP6771512B2 (ja) | 2012-08-23 | 2018-06-29 | 抗不安薬組成物、製剤および使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20140057988A1 (enExample) |
| EP (2) | EP3878442A1 (enExample) |
| JP (2) | JP6722453B2 (enExample) |
| KR (1) | KR20150096370A (enExample) |
| CN (1) | CN104902883A (enExample) |
| AU (1) | AU2013305580A1 (enExample) |
| BR (1) | BR112015003796A2 (enExample) |
| IL (1) | IL237340A0 (enExample) |
| MX (1) | MX2015002378A (enExample) |
| SG (1) | SG11201501292UA (enExample) |
| WO (1) | WO2014031975A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140275278A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| SG11201507358VA (en) * | 2013-03-15 | 2015-10-29 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| AU2014250756B2 (en) | 2013-04-12 | 2019-03-07 | Icahn School Of Medicine At Mount Sinai | Method for treating post-traumatic stress disorder |
| HRP20211629T1 (hr) | 2013-09-13 | 2022-02-04 | National University Corporation Chiba University | Primjena r-ketamina i njegove soli kao lijekova |
| EP3179993B1 (en) | 2014-08-13 | 2021-01-20 | Janssen Pharmaceutica NV | Esketamine for use in a method for the treatment of depression |
| JP6757537B2 (ja) * | 2014-08-29 | 2020-09-23 | 公益財団法人ヒューマンサイエンス振興財団 | 神経疾患モデル動物の製造方法及び神経疾患モデル動物 |
| CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| EP3085366A1 (en) * | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| JP2018521007A (ja) * | 2015-05-22 | 2018-08-02 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの治療的使用 |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| CN105249531A (zh) * | 2015-08-06 | 2016-01-20 | 云南中烟工业有限责任公司 | 一种金丝楠木提取物的制备方法及其应用 |
| PL3922249T3 (pl) * | 2015-09-08 | 2024-07-29 | The Children's Hospital Of Philadelphia | Diagnozowanie i leczenie zaburzeń lękowych |
| WO2017087691A1 (en) * | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| FR3075038B1 (fr) * | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| MX2020006650A (es) | 2017-12-22 | 2020-11-06 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| CN118453559A (zh) | 2018-02-15 | 2024-08-09 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| CA3099293A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020041329A1 (en) * | 2018-08-20 | 2020-02-27 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| WO2020171207A1 (ja) | 2019-02-22 | 2020-08-27 | ハリマ化成株式会社 | 固形ろう付け材の塗布方法、塗布物の製造方法、塗布装置、および、ロール形状の固形ろう付け材 |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| EP3968977A4 (en) * | 2019-05-15 | 2023-01-11 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| PT3976012T (pt) * | 2019-05-31 | 2024-04-09 | Afyx Therapeutics As | Administração intranasal de cetamina a doentes com cefaleia em salvas |
| PH12022551856A1 (en) | 2020-01-22 | 2024-01-03 | Seelos Therapeutics Inc | Reducing side effects of nmda antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP1103256A1 (de) * | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| CN101466364A (zh) * | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
| CN101765582A (zh) * | 2007-04-26 | 2010-06-30 | 奥斯拜客斯制药有限公司 | 氘标记的氯胺酮 |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
-
2013
- 2013-08-23 AU AU2013305580A patent/AU2013305580A1/en not_active Abandoned
- 2013-08-23 MX MX2015002378A patent/MX2015002378A/es unknown
- 2013-08-23 KR KR1020157007330A patent/KR20150096370A/ko not_active Withdrawn
- 2013-08-23 US US13/975,060 patent/US20140057988A1/en not_active Abandoned
- 2013-08-23 BR BR112015003796A patent/BR112015003796A2/pt not_active IP Right Cessation
- 2013-08-23 EP EP21156344.0A patent/EP3878442A1/en active Pending
- 2013-08-23 EP EP13831683.1A patent/EP2887930A4/en not_active Ceased
- 2013-08-23 WO PCT/US2013/056424 patent/WO2014031975A1/en not_active Ceased
- 2013-08-23 JP JP2015528691A patent/JP6722453B2/ja active Active
- 2013-08-23 CN CN201380055487.7A patent/CN104902883A/zh active Pending
- 2013-08-23 SG SG11201501292UA patent/SG11201501292UA/en unknown
-
2015
- 2015-02-22 IL IL237340A patent/IL237340A0/en unknown
-
2017
- 2017-09-25 US US15/714,211 patent/US20180235906A1/en not_active Abandoned
-
2018
- 2018-06-29 JP JP2018124196A patent/JP6771512B2/ja active Active
-
2021
- 2021-08-02 US US17/391,808 patent/US20220160655A1/en not_active Abandoned
-
2024
- 2024-10-28 US US18/928,612 patent/US20250255834A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096439A1 (es) | Forma de dosificación resistente al uso indebido que contiene una o más partículas | |
| JP2016028090A5 (enExample) | ||
| JP2016106150A5 (enExample) | ||
| JP2015523407A5 (enExample) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| JP2016518337A5 (enExample) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| IN2014MN01919A (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2013166781A5 (enExample) | ||
| EP3162804A8 (en) | New benzodiazepine derivative and use thereof | |
| AR100368A1 (es) | Tratamiento de trastornos respiratorios | |
| NZ719087A (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| JP2014058509A5 (enExample) | ||
| JP2016538295A5 (enExample) | ||
| HRP20220701T1 (hr) | Spojeni benzazepini za liječenje touretteova sindroma | |
| JP2016528283A5 (enExample) | ||
| CY1120749T1 (el) | Φαρμακευτικες δοσολογικες μορφες | |
| HRP20160811T1 (hr) | Upotreba odiparcila u liječenju mukopolisaharidoze | |
| ES2436344B1 (es) | Composición farmacéutica de diacetilmorfina y naloxona para administración oral | |
| JP2017515849A5 (enExample) | ||
| JP2014240383A5 (enExample) |